Table 5.
Association between worsening renal function by week 16 and subsequent clinical outcomes
| Subsequent clinical outcome | WRF rateb (events) | No WRF rateb (events) | Unadjusteda | Adjusted | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |||
| HFH or CV deathc | 48.4% (249) | 30.0% (973) | 1.41 (1.22–1.62) | <0.001 | 1.28 (1.11–1.47) | <0.001 |
| HFH or all‐cause deathd | 50.8% (261) | 31.7% (1030) | 1.40 (1.22–1.60) | <0.001 | 1.24 (1.08–1.43) | 0.002 |
| CV deathe | 16.3% (107) | 10.5% (393) | 1.35 (1.08–1.67) | 0.007 | 1.25 (1.01–1.56) | 0.044 |
CI, confidence interval; CV, cardiovascular; HFH, heart failure hospitalization; HR, hazard ratio; WRF, worsening renal function.
All models include baseline creatinine and time from prior hospitalization or intravenous diuretics to week 16 visit date (categorized).
Rates computed as the number of events per 100 patient‐years of follow‐up.
Adjusted for worsening heart failure event, angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker use, bilirubin, chloride, hemoglobin, duration of heart failure, gamma‐glutamyl transferase, N‐terminal pro‐brain natriuretic peptide, New York Heart Association class, pulse, QT interval corrected with Fridericia's formula, urate and history of: myocardial infarction, peripheral artery disease, percutaneous coronary intervention.
Adjusted for worsening heart failure event, angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker use, albumin, bilirubin, chloride, hemoglobin, duration of heart failure, gamma‐glutamyl transferase, N‐terminal pro‐brain natriuretic peptide, New York Heart Association class, pulse, QT interval corrected with Fridericia's formula, urate and history of: hyperlipidemia, myocardial infarction, peripheral artery disease.
Adjusted for age, albumin, beta‐blocker use, bilirubin, chloride, hemoglobin, duration of heart failure, N‐terminal pro‐brain natriuretic peptide, New York Heart Association class, systolic blood pressure, race/region, urate and history of: anemia, myocardial infarction, peripheral artery disease.